Home | About PM | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Pharmacognosy Magazine
Search Article 
  
Advanced search 
 
ORIGINAL ARTICLE
Year : 2013  |  Volume : 9  |  Issue : 33  |  Page : 14-22

Potential antianxiety activity of Fumaria indica: A preclinical study


1 Neuropharmacology Research Laboratory, Department of Pharmaceutical Engineering, Indian Institute of Technology (Banaras Hindu University), Varanasi, India
2 Department of Molecular and Human Genetics, Faculty of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India
3 Stettiner Str. 1, D-76138 Karlsruhe, Germany; Retired Head of Pharmacology Research Laboratories, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany

Correspondence Address:
Vikas Kumar
Neuropharmacology Research Laboratory, Department of Pharmaceutical Engineering, Indian Institute of Technology (Banaras Hindu University), Varanasi- 221 005, Uttar Pradesh
India
Login to access the Email id

Source of Support: Financial assistance provided by the Indian Council of Medical Research (ICMR), Government of India, New Delhi., Conflict of Interest: None


PMID: 23661988

Rights and PermissionsRights and Permissions

Background: In the view of diverse CNS modulating properties of Fumaria indica, present study was planned to evaluate its putative anxiolytic activity in behavioural models of rats, followed by elucidation of mechanism of observed activity through biochemical estimations. Materials and Methods: Effects of seven daily 100, 200 and 400 mg/kg oral doses of a Fumaria indica extract (FI) was compared with those of an acute oral dose (5 mg/kg) of lorazepam in a battery of rat models consisting of open-field, elevated plus and zero maze, social interaction, and novelty induced feeding tests. Results: Dose dependant antianxiety effects of FI observed in all tests were qualitatively similar to those of the reference anxiolytic drug. Although FI treatments did not alter the concentrations of noradrenaline and serotonin in hippocampus and hypothalamus, concentrations of both these monoamines were dose dependently elevated in prefrontal cortex of FI treated animals. Flunitrazepam binding in brain frontal cortex was also elevated by the extract. Moreover, higher levels of brain expressions of the cytokines TNF-α, IL-1β, and IL-10 observed in animals with prior experience on elevated plus maze were almost completely reversed by the lowest dose of FI tested in the behavioral models. Conclusion: Taken together, these observations strongly suggest that FI is a functionally novel type of antianxiety agent, and that inhibition of cytokine expressions in the brain could be involved in its mode of action.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3337    
    Printed89    
    Emailed0    
    PDF Downloaded14    
    Comments [Add]    

Recommend this journal